Medical device company IDEXX Laboratories, Inc. (NASDAQ: IDXX) on Monday reported higher revenues and net income for the fourth quarter of 2024.
- Fourth-quarter revenues increased 6% annually to $954.3 million; organic revenue growth was 6%
- Net income attributable to shareholders moved up to $216.1 million in Q4 from $194.5 million a year earlier
- On a per-share basis, fourth-quarter earnings rose to $2.62 from $2.32 in Q4 2023
- For fiscal 2025, the management expects revenues to be in the range of $4.06 billion to $4.17 billion, reflecting a growth of 4-7%
- Full-year organic revenue growth is expected to be between 6% and 9%
- The management is looking for earnings of $11.74 per share to $12.24 per share for FY25, an increase of 10-15% on a reported basis
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
BLK Q4 Preview: BlackRock appears poised for another earnings beat
BlackRock, Inc. (NYSE: BLK), the largest asset management company, is set to publish its fourth-quarter 2025 results next week. The update is expected to shed light on how the firm’s
A look at Best Buy’s (BBY) progress on its growth strategy
Shares of Best Buy Co., Inc. (NYSE: BBY) fell over 3% on Wednesday. The stock has dropped 17% over the past 12 months. The consumer electronics retailer delivered sales and
